Humana Inc. (NYSE:HUM) Shares Purchased by Argent Trust Co

Argent Trust Co raised its position in shares of Humana Inc. (NYSE:HUM) by 42.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,760 shares of the insurance provider’s stock after buying an additional 521 shares during the quarter. Argent Trust Co’s holdings in Humana were worth $447,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. FPC Investment Advisory Inc. acquired a new position in Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC acquired a new stake in shares of Humana in the fourth quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA raised its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the last quarter. OFI Invest Asset Management acquired a new position in shares of Humana during the fourth quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. increased its position in Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 60 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Up 1.6 %

HUM stock opened at $294.97 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $35.60 billion, a P/E ratio of 29.65, a P/E/G ratio of 2.05 and a beta of 0.62. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company’s 50 day simple moving average is $265.55 and its 200-day simple moving average is $270.65.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.20%. Humana’s dividend payout ratio is 35.58%.

Wall Street Analysts Forecast Growth

HUM has been the subject of several recent analyst reports. Truist Financial increased their price target on Humana from $290.00 to $325.00 and gave the stock a “hold” rating in a research note on Friday. StockNews.com raised shares of Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. Guggenheim began coverage on shares of Humana in a research report on Wednesday. They set a “buy” rating and a $326.00 price target on the stock. Morgan Stanley decreased their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Finally, Mizuho boosted their target price on Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $288.60.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.